Sygnature Chemical Services and RespiVert Provide Update on Successful Discovery Collaboration

16th November 2009

Sygnature Chemical Services, a leading provider of medicinal and computational chemistry services to the global pharmaceutical industry, and RespiVert, a small molecule drug discovery company developing improved treatments for patients with severe respiratory disease, today provided an update on their research collaboration, first announced in January 2008.

Under the terms of the agreement Sygnature have provided a comprehensive medicinal chemistry discovery platform for two of RespiVert’s leading programmes aimed at identifying novel therapeutic agents for the treatment of poorly controlled, steroid refractory pulmonary disease.

Dr John Murray, director of medicinal chemistry at RespiVert said, “We selected Sygnature as the first of our principal collaborators, in September 2007, based upon their outstanding track record in providing ‘state-of the-art’ medicinal chemistry to drug discovery clients in the UK and abroad. After working in close partnership with our Sygnature colleagues throughout this period, our high expectations of them have been fully realised.”

“Together, we have established an integrated drug discovery team which has created a valuable portfolio of IP assets and delivered preclinical candidates in two of our respiratory disease-focused programmes. I have been particularly impressed with the intellectual input that Sygnature’s scientists have made to our research enterprise; their flair for providing innovative solutions to difficult problems and their consistently high level of productivity. We are delighted with the success of our association with Sygnature and pleased to acknowledge the important contribution they have made to Respivert’s accomplishments over the last two years,” added Dr Murray.

Commenting on the partnership, Dr Simon Hirst, Sygnature’s CEO said, “The discovery collaboration between RespiVert and Sygnature has been extremely fruitful and two projects have delivered candidate molecules, in less than 24 months, which are on-track to enter the clinic in 2010. I am proud of the contribution made by Sygnature’s medicinal chemists to RespiVert’s drug discovery programmes.”

“The success of the collaboration with RespiVert confirms our ability to create value for our clients by providing ‘top tier’ science in a close working relationship, that puts an emphasis on shared goals and values. This ethos, together with complete transparency in our dealings with clients, are the principal attributes that Sygnature brings to its professional interactions. We look forward to continuing working with RespiVert in the future, and wish them every success in progressing the clinical development of their drug candidates,” Dr Hirst concluded.

More About This Company